logo
'Significant' turbulence on a Delta flight leaves 25 passengers hospitalized: How to avoid getting injured when your plane experiences it

'Significant' turbulence on a Delta flight leaves 25 passengers hospitalized: How to avoid getting injured when your plane experiences it

Yahoo6 days ago
Experts explain how severe turbulence on flights can cause injuries — and how to minimize your risk.
A Delta Air Lines flight from Salt Lake City to Amsterdam experienced "significant" turbulence on Wednesday and was forced to land in Minneapolis, where 25 passengers were taken to hospitals for treatment, the airline said.
The plane, an Airbus A330-900 with 275 passengers and 13 crew members on board, was about two hours into its nine-hour flight when it was diverted to Minneapolis-St. Paul International Airport, landing at 7:45 p.m. local time. Paramedics boarded the aircraft and 25 passengers were "transported to local hospitals for evaluation and care," Delta said in a statement.
One passenger told ABC News that people who weren't wearing seat belts were thrown into the air.
"They hit the ceiling, and then they fell to the ground," Leeann Nash said. "The carts also hit the ceiling and fell to the ground, and people were injured. It happened several times, so it was really scary."
Recent studies have shown that air turbulence is on the rise, thanks in part to climate change. So too are reports of injuries due to severe turbulence. We asked doctors about what types of injuries they've been seeing — and how to avoid them.
How can you get injured during turbulence?
There are a few possibilities. "First, an unrestrained passenger may be thrown about by turbulence, leading to falls or head injuries," Dr. Ashley Panas, chief flight physician at Vanderbilt LifeFlight, tells Yahoo Life. "Second, unrestrained objects may strike passengers."
A range of injuries can happen. "Injuries can be minor to severe, and while very uncommon, they can be fatal," Dr. Lewis Nelson, professor at the Rutgers New Jersey Medical School, tells Yahoo Life. "Concerning injuries occur when people are tossed around by unexpected, severe and rapid plane movements."
The plane can suddenly jerk when moderate to severe turbulence hits, Dr. Erik Antonsen, associate professor at Baylor College of Medicine, tells Yahoo Life. "If passengers are standing in the aisle, they can lose their balance and fall, sometimes onto other passengers," he says. "Those in seats can experience whiplash-type injuries and can hit their heads against the window or seat backs. Flail injuries of the extremities can occur as arms and legs can get slammed against whatever hard surfaces are nearby."
The most troubling injuries happen when people are thrown upward during turbulence, Nelson says. "Objects such as food carts, computers or luggage can also be set in motion and can cause injury, including burns from coffee," he says.
What do turbulence injuries usually involve?
It's a lot of head injuries, Dr. Russ Kino, emergency medicine physician at Providence Saint John's Health Center in Santa Monica, Calif., tells Yahoo Life.
"The most common thing I've seen is mostly head lacerations," he says. "When people don't have their seatbelts on, their heads hit the plastic above them during turbulence. That plastic often breaks and there are a lot of lacerations. There's a lot of picking pieces of plastic from the scalp."
Kino says he once treated passengers who hit rough turbulence while flying from Bali to Australia. "We had 100 people come to the ER, and they all had lacerations and pieces of plastic in the scalp."
But passengers can also have blunt injuries to the torso or the arms and legs that lead to bone fractures, joint sprains, bleeding or internal organ injury, Nelson says. "The most concerning injuries occur when people are thrown upward relative to the plane during turbulence," he says. "Hitting the ceiling headfirst can lead to head injury or to an axial loading injury in which the spine is compressed and injured."
If someone is severely injured during a flight, the pilot may be required to divert and land at a closer airport to get quick medical attention, Panas says.
How to avoid getting hurt on a flight
Kino stresses the importance of wearing your seatbelt — and not just when the crew announces there is turbulence ahead. "Every moment you can, you should just wear your seatbelt," he says.
Dr. Christopher E. San Miguel, associate professor at the Ohio State University Wexner Medical Center, agrees. "People are almost exclusively injured in turbulence events by falling or being thrown around the cabin," he tells Yahoo Life. "It can occur without warning, which is why it's important to remain buckled, even when the light is not illuminated."
Antonsen also recommends limiting how often you're out of your seat. "Don't be up and moving about the cabin more than is necessary, and don't stand in the aisles for long periods," he says. "Many people fly frequently and some may tune out crew announcements, but the crew is your most important source of information that can help you avoid injury on flights. Be sure to listen when they are talking."
Despite all of this, San Miguel stresses that turbulence injuries are relatively rare. "It is important to point out that the odds of being injured by turbulence on a commercial flight is quite low," he says.
This article was originally published on Sept. 1, 2023 and has been updated.
Solve the daily Crossword
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Minneapolis fire stations install saunas to help crews clear out smoke, toxins
Minneapolis fire stations install saunas to help crews clear out smoke, toxins

CBS News

time6 hours ago

  • CBS News

Minneapolis fire stations install saunas to help crews clear out smoke, toxins

There's no doubt firefighting is a dangerous job, but some of the biggest risks aren't just the flames. It's what lingers afterwards. It's why Minneapolis Fire Departments have been installing saunas at their stations. Steve Shapira is the founder of the Minneapolis Fire Foundation, an organization that supports the health and safety of Minneapolis Fire Fighters. "One of the things we're trying to do is help firefighters have a post fire place to go and get some of these toxins away from their body," said Shapira. "What we're really trying to do is stop the absorption of the soot and smoke that is on the surface of their skin, before it can get into their fat, get into their bloodstream, and get into their organs." For him, the mission is personal. After 17 years as a St. Paul fire captain, Shapira was forced to retire after developing blood cancer, likely caused by exposure to toxins. "It's kind of become my mission since I got sick 10-plus years ago to help keep firefighters healthy and so this is just one more tool in our tool box to kind of have firefighters go down that road of a long, safe, healthy career," Shapria said. According to the International Association of Fire Fighters, occupational cancer is the leading cause of line-of-duty death in the fire service. in 2023, 72% of firefighter deaths were from cancer. So far, five fire stations in Minneapolis have the saunas. The goal is to equip the remaining 14 and the training station. CJ Schertner is a captain with the Minneapolis Fire Department. He says the saunas are doing what a shower can't. "You're showering, you're scrubbing, you still come out of that shower smelling like smoke," Schertner said. The saunas are benefiting in other ways as well. "It's also been a nice thing for people to use just for their mental health. It's a good thing to help rejuvinate you a little bit," said Schertner. Research is still underway on just how effective post-fire saunas are for removing carcinogens, but for firefighters, it's one more defense in a job full of hidden risks.

Hawaiian Airlines to add premium economy in A330 overhaul
Hawaiian Airlines to add premium economy in A330 overhaul

Travel Weekly

time8 hours ago

  • Travel Weekly

Hawaiian Airlines to add premium economy in A330 overhaul

Hawaiian Airlines' fleet of two dozen Airbus A330 aircraft will be retrofitted to accommodate the carrier's first premium economy cabin. New interiors will also have updated lie-flat seats in business class and upgraded seats in the main cabin. Parent company Alaska Air Group did not provide a timeline for the retrofits, but said it will be making a substantial investment "over the next few years," and that Airbus 330 widebody planes will remain dedicated to Hawaii flying.

DiaMedica Therapeutics Appoints Julie Krop, MD, as Chief Medical Officer
DiaMedica Therapeutics Appoints Julie Krop, MD, as Chief Medical Officer

Yahoo

time17 hours ago

  • Yahoo

DiaMedica Therapeutics Appoints Julie Krop, MD, as Chief Medical Officer

MINNEAPOLIS, August 06, 2025--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced the appointment of Julie Krop, MD, as Chief Medical Officer (CMO), effective immediately. Dr. Krop will succeed Dr. Lorianne Masuoka, who has resigned from her position as CMO for personal reasons. "We are pleased to welcome Dr. Krop to our executive leadership team," said Rick Pauls, President and CEO of DiaMedica. "Her extensive experience in the biopharma industry and track record of advancing innovative therapeutics from proof of concept to approval will be invaluable to our team as we advance toward late-stage clinical development of DM199. Additionally, Dr. Krop's previous experience in preeclampsia drug development will be beneficial as we work to provide a treatment for this significant unmet need. On behalf of the DiaMedica team, I thank Lorianne for her guidance and dedication, which helped position DiaMedica for success. We wish her the best in her future endeavors." Dr. Krop added, "I'm excited to join DiaMedica at such a pivotal time in its growth. DM199 has the potential to be a fully disease-modifying therapy for patients with preeclampsia, as demonstrated by the recent Phase 2 Part 1a interim trial results. I look forward to helping guide the company's clinical development strategy as we advance this first in class drug candidate into later stage development for both preeclampsia and acute ischemic stroke – two areas of urgent unmet need where no approved treatments currently exist." Dr. Krop has more than 20 years of experience as a strategic physician executive with leadership experience spanning multiple therapeutic and orphan indications in both pre-commercial and commercial organizations. She joins DiaMedica from PureTech Health, where she was CMO and Head of Development, leading multiple rare disease programs from preclinical development through Phase 2 trials. Prior, she served as CMO at Freeline Therapeutics, where she helped drive a successful IPO and oversaw three clinical stage gene therapy programs. Before that, Dr. Krop was CMO and Executive Vice President at AMAG Pharmaceuticals, where she was involved in the approval of three drugs and worked on the development of an orphan drug candidate for the treatment of severe preeclampsia. Previously, Dr. Krop has held senior development roles at Vertex Pharmaceuticals, Stryker Regenerative Medicine, Peptimmune, Millennium Pharmaceuticals, and Pfizer. Dr. Krop received her MD from Brown University School of Medicine and completed her internal medicine residency at Georgetown University Hospital. She also completed fellowships in epidemiology, clinical trial design and endocrinology at Johns Hopkins School of Medicine. Dr. Krop is board-certified in Endocrinology. About DiaMedica Therapeutics Inc. DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious ischemic diseases with a focus on preeclampsia, fetal growth restriction and acute ischemic stroke. DiaMedica's lead candidate DM199 is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of acute ischemic stroke, preeclampsia and other vascular diseases. For more information visit the Company's website at Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) In connection with Dr. Krop's appointment, DiaMedica granted her an inducement stock option to purchase 450,000 shares of DiaMedica's common stock pursuant to the DiaMedica Therapeutics, Inc. 2021 Employment Inducement Incentive Plan. The inducement grant was approved by the Company's compensation committee of the board of directors and will be effective as of Dr. Krop's first date of employment, August 11, 2025, and was a material inducement to her acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of her compensation. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and forward-looking information that are based on the beliefs of management and reflect management's current expectations. When used in this press release, the words "anticipates," "believes," "continue," "could," "estimates," "expects," "intends," "may," "plans," "potential," "should," "seek," "might," "project," "target," "aim," or "will," the negative of these words or such variations thereon or comparable terminology and the use of future dates are intended to identify forward-looking statements and information. The forward-looking statements and information in this press release include statements regarding the Company's expectations regarding the anticipated clinical benefits and success of DM199 for the treatment of preeclampsia and acute ischemic stroke. Such statements and information reflect management's current view and DiaMedica undertakes no obligation to update or revise any of these statements or information. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Applicable risks and uncertainties include, among others, risks and uncertainties relating to the clinical expansion into preeclampsia and that trial; regulatory applications and related filing and approval timelines; the possibility of unfavorable results from DiaMedica's other ongoing or future clinical trials of DM199; the risk that existing preclinical and clinical data may not be predictive of the results of ongoing or later clinical trials; the potential direct or indirect impact of hospital and medical facility staffing shortages, increased tariffs and worldwide global supply chain disruptions on DiaMedica's business and clinical trials; DiaMedica's reliance on collaboration with third parties to conduct clinical trials; DiaMedica's ability to continue to obtain funding for its operations, including funding necessary to complete current and planned clinical trials and obtain regulatory approvals for DM199 for preeclampsia and acute ischemic stroke and the risks identified under the heading "Risk Factors" in DiaMedica's annual report on Form 10-K for the fiscal year ended December 31, 2024 filed with the U.S. Securities and Exchange Commission (SEC) and subsequent SEC reports, including DiaMedica's quarterly report on Form 10-Q for the quarterly period ended March 31, 2025. The forward-looking information contained in this press release represents the expectations of DiaMedica as of the date of this press release and, accordingly, is subject to change after such date. Readers should not place undue importance on forward-looking information and should not rely upon this information as of any other date. While DiaMedica may elect to, it does not undertake to update this information at any particular time except as required in accordance with applicable laws. View source version on Contacts Corporate Contact: Scott Kellen, Chief Financial Officer(763) 496-5118 | skellen@ Investor Contact: Mike Moyer, Managing Director, LifeSci Advisorsmmoyer@ Media Contact: Madelin Hawtin, LifeSci Communicationsmhawtin@ Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store